New research shows that Britain’s fastest-growing privately-owned pharmaceutical businesses are facing down tough headwinds to deliver stellar rates of growth. The top 10 businesses in the sector have all seen their sales grow by an average of at least 43% a year over the past two years according to the Alantra Pharma Fast 50, an annual ranking of non-listed UK pharmaceutical companies.
The Alantra Pharma Fast 50 ranks the UK’s fastest-growing, privately-owned pharmaceutical businesses according to revenue growth over the past two years. On this basis, Qualasept Pharmaxo is currently the fastest-growing privately-owned pharmaceuticals business in the UK, having grown its sales by an average of 69% over the past two years.
The Alantra Pharma Fast 50 includes analysis of businesses grouped into four distinct sub-sectors: pharma outsourcing; pharmacy chains; development, wholesale and supply (DWS); and consulting. This year’s leaders are:
- Pharma outsourcing: Simbec-Orion, a boutique contract research organisation which has delivered sales growth averaging 49% a year over the past two years.
- Pharmacy chains: Gorgemead, which trades as Cohens Chemist, where sales are up by 51% a year over the past two years.
- DWS: Immunocore, a biopharma business, with sales up by 61% a year over the past two years.
- Consulting: Random42, a specialist in medical animations, with sales up by 34% a year over the past two years.
Tom Cowap, a Director in Alantra’s UK advisory business, said: “Despite the fact that the industry is facing difficult challenges including the spectre of Brexit, tough pressure on margins, demanding regulatory scrutiny and issues such as the patent cliff, the companies in the Alantra Pharma Fast 50 have repeatedly managed to grow their sales at an impressive rate.”